Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Other Operating Expenses (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Other Operating Expenses for 6 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses rose 10.58% year-over-year to $13.1 million, compared with a TTM value of $49.4 million through Dec 2025, up 0.66%, and an annual FY2025 reading of $49.4 million, up 0.66% over the prior year.
  • Other Operating Expenses was $13.1 million for Q4 2025 at Cytek Biosciences, up from $11.7 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $13.1 million in Q4 2025 and bottomed at -$6.2 million in Q1 2023.
  • Average Other Operating Expenses over 5 years is $7.5 million, with a median of $10.3 million recorded in 2022.
  • The sharpest move saw Other Operating Expenses crashed 226.69% in 2023, then skyrocketed 375.31% in 2024.
  • Year by year, Other Operating Expenses stood at $8.3 million in 2021, then rose by 8.73% to $9.0 million in 2022, then rose by 28.03% to $11.6 million in 2023, then grew by 2.72% to $11.9 million in 2024, then increased by 10.58% to $13.1 million in 2025.
  • Business Quant data shows Other Operating Expenses for CTKB at $13.1 million in Q4 2025, $11.7 million in Q3 2025, and $12.1 million in Q2 2025.